Literature DB >> 23592433

Bayesian analysis and classification of two enzyme-linked immunosorbent assay tests without a gold standard.

Jingyang Zhang1, Kathryn Chaloner, James H McLinden, Jack T Stapleton.   

Abstract

Reconciling two quantitative enzyme-linked immunosorbent assay tests for an antibody to an RNA virus, in a situation without a gold standard and where false negatives may occur, is the motivation for this work. False negatives occur when access of the antibody to the binding site is blocked. On the basis of the mechanism of the assay, a mixture of four bivariate normal distributions is proposed with the mixture probabilities depending on a two-stage latent variable model including the prevalence of the antibody in the population and the probabilities of blocking on each test. There is prior information on the prevalence of the antibody, and also on the probability of false negatives, and so a Bayesian analysis is used. The dependence between the two tests is modeled to be consistent with the biological mechanism. Bayesian decision theory is utilized for classification.The proposed method is applied to the motivating data set to classify the data into two groups: those with and those without the antibody. Simulation studies describe the properties of the estimation and the classification. Sensitivity to the choice of the prior distribution is also addressed by simulation. The same model with two levels of latent variables is applicable in other testing procedures such as quantitative polymerase chain reaction tests, where false negatives occur when there is a mutation in the primer sequence.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Bayesian analysis; Bayesian decision theory; diagnostic testing; mixture model

Mesh:

Substances:

Year:  2013        PMID: 23592433      PMCID: PMC3825773          DOI: 10.1002/sim.5816

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  27 in total

1.  Bayesian approaches to modeling the conditional dependence between multiple diagnostic tests.

Authors:  N Dendukuri; L Joseph
Journal:  Biometrics       Date:  2001-03       Impact factor: 2.571

Review 2.  Estimation of sensitivity and specificity of diagnostic tests and disease prevalence when the true disease state is unknown.

Authors:  C Enøe; M P Georgiadis; W O Johnson
Journal:  Prev Vet Med       Date:  2000-05-30       Impact factor: 2.670

3.  Estimating disease prevalence in the absence of a gold standard.

Authors:  Michael A Black; Bruce A Craig
Journal:  Stat Med       Date:  2002-09-30       Impact factor: 2.373

4.  GBV-C/hepatitis G virus infection and non-Hodgkin lymphoma: a case control study.

Authors:  Mel Krajden; Amanda Yu; Heather Braybrook; Agnes S Lai; Annie Mak; Ron Chow; Darrel Cook; Raymond Tellier; Martin Petric; Randy D Gascoyne; Joseph M Connors; Angela R Brooks-Wilson; Richard P Gallagher; John J Spinelli
Journal:  Int J Cancer       Date:  2010-06-15       Impact factor: 7.396

5.  Latent variable modeling of diagnostic accuracy.

Authors:  I Yang; M P Becker
Journal:  Biometrics       Date:  1997-09       Impact factor: 2.571

Review 6.  Estimation of test error rates, disease prevalence and relative risk from misclassified data: a review.

Authors:  S D Walter; L M Irwig
Journal:  J Clin Epidemiol       Date:  1988       Impact factor: 6.437

7.  Receiver operator characteristic (ROC) analysis without truth.

Authors:  R M Henkelman; I Kay; M J Bronskill
Journal:  Med Decis Making       Date:  1990 Jan-Mar       Impact factor: 2.583

8.  High prevalence of GB virus C/hepatitis G virus infection in different risk groups of HIV-infected patients.

Authors:  P. Clevenberg; J. Durant; P. Halfon; A. Tran; T. Manos; V. Rahelinirina; G. Yang; S. Benzaken; D. Ouzan; P. Rampal; P. Dellamonica
Journal:  Clin Microbiol Infect       Date:  1998-01       Impact factor: 8.067

9.  Detection of antibodies to a putative hepatitis G virus envelope protein.

Authors:  M Tacke; K Kiyosawa; K Stark; V Schlueter; B Ofenloch-Haehnle; G Hess; A M Engel
Journal:  Lancet       Date:  1997-02-01       Impact factor: 79.321

Review 10.  GB virus type C interactions with HIV: the role of envelope glycoproteins.

Authors:  Emma L Mohr; Jack T Stapleton
Journal:  J Viral Hepat       Date:  2009-09-15       Impact factor: 3.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.